{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000085","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.946200+00:00","generated_at":"2026-05-30T19:29:17.956525+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"AEON Biopharma posts new corporate presentation highlighting prabotulinumtoxinA biosimilar","bullets":["Corporate presentation posted on IR site on October 7, 2024, used for investor meetings.","Slide deck focuses on prabotulinumtoxinA as a potential biosimilar for therapeutic indications.","No financial results, guidance, or material corporate events disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000085","json":"https://secwatch.observer/filing/0001837607-24-000085.json","markdown":"https://secwatch.observer/filing/0001837607-24-000085.md","text":"https://secwatch.observer/filing/0001837607-24-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000085/0001837607-24-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000085/aeon-20241007x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:29:17.956525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}